942316-98-5

Basic information

• Product Name: methyl (4-(2-bromoacetyl)phenyl)carbamate
• Synonyms: methyl (4-(2-bromoacetyl)phenyl)carbamate
• CAS NO: 942316-98-5
• Molecular Weight: 272.098
• Mol File: 942316-98-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: methyl (4-(2-bromoacetyl)phenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (4-(2-bromoacetyl)phenyl)carbamate(942316-98-5)
• EPA Substance Registry System: methyl (4-(2-bromoacetyl)phenyl)carbamate(942316-98-5)

Safety Data

• Hazardous Substances Data: 942316-98-5(Hazardous Substances Data)

Upstream product

• 99-92-3 p-aminobenzophenone 
• 60677-43-2 methyl N-(4-acetylphenyl)carbamate 

Relevant articles and documents

Synthesis and in vitro antimycobacterial activity of novel n-arylpiperazines containing an ethane-1,2-diyl connecting chain

Novel 1-(2-{3-/4-[(alkoxycarbonyl)amino]phenyl}-2-hydroxyethyl)-4-(2-fluorophenyl)-piperazin-1-ium chlorides (alkoxy = methoxy to butoxy; 8a-h) have been designed and synthesized through multistep reactions as a part of on-going research programme focused

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, R3, R4, R8a, R11 and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.